Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia
Pembrolizumab combination therapy offers substantial survival and QALY gains for R/M HNSCC patients with an ICER lower than the Colombian willingness to pay making it a cost-effective treatment in Colombia.
Authors
- Christopher M. Black (ORCID: https://orcid.org/0000-0003-2934-108X)
- J. Urrego-Reyes (ORCID: https://orcid.org/0000-0001-8306-8470)
- M. Rojas
- Rebekah H. Borse
- Anubhav Patel
- Hernán Jaramillo (ORCID: https://orcid.org/0009-0008-9130-1875)
- Carlos Marrugo Arnedo
- Oscar Eduardo Realpe
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1080/13696998.2025.2510807
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.85